𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Imatinib mesylate causes growth deceleration in pediatric patients with chronic myelogenous leukemia

✍ Scribed by Maynika V. Rastogi; Linda Stork; Brian Druker; Carolyn Blasdel; Thuan Nguyen; Bruce A. Boston

Book ID
112168124
Publisher
John Wiley and Sons
Year
2012
Tongue
English
Weight
462 KB
Volume
59
Category
Article
ISSN
1545-5009

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Imatinib mesylate therapy reduces bone m
Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia
✍ Carlos E. Bueso-Ramos; Jorge Cortes; Moshe Talpaz; Susan O'Brien; Francis Giles; πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 189 KB πŸ‘ 1 views

## Abstract ## BACKGROUND Reticulin‐stained bone marrow fibrosis is associated with a poor prognosis in patients with chronic myelogenous leukemia (CML). Resolution of fibrosis with therapy may improve patient outcome. ## METHODS The effect of imatinib therapy on bone marrow fibrosis was evaluat

Persistent neutropenia in chronic myelog
Persistent neutropenia in chronic myelogenous leukemia in chronic phase treated with imatinib mesylate
✍ Yu-Yan Hwang; Eric Tse; Jason C.C. So; Thomas S.K. Wan; Yok-Lam Kwong πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 110 KB πŸ‘ 1 views

A physician or a group of physicians considers presentation and evolution of a real clinical case, reacting to clinical information and data (boldface type). This is followed by a discussion/commentary.

Outcome of patients with Philadelphia ch
Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure
✍ Hagop Kantarjian; Susan O'Brien; Moshe Talpaz; Gautam Borthakur; Farhad Ravandi; πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 150 KB πŸ‘ 1 views

## Abstract ## BACKGROUND. The prognosis of patients with chronic myelogenous leukemia (CML) after failure of imatinib mesylate therapy is not well documented. ## METHODS. The outcome of 420 patients with CML post‐imatinib failure (resistance‐recurrence in 374; toxicities in 46) were reviewed in

The significance of myelosuppression dur
The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase
✍ Thomas B. Sneed; Hagop M. Kantarjian; Moshe Talpaz; Susan O'Brien; Mary Beth Rio πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 82 KB πŸ‘ 1 views

## Abstract ## BACKGROUND Imatinib mesylate induces high rates of hematologic and cytogenetic response in patients with chronic myelogenous leukemia (CML). During therapy with imatinib, up to 45% of patients with CML reportedly experience myelosuppression β‰₯ Grade 3, requiring interruption of thera